News - Licensing, Genzyme


Current filters:


Popular Filters

Alnylam gets upfront $22.5 million in RNAi link with Genzyme


French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi


As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Sanofi surprises Osiris by pulling out of Prochymal deal


Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

PTC Therapeutics and Genzyme restructuring ataluren collaboration


Privately-held PTC Therapeutics and fellow USA-based Genzyme, now part of French drug major Sanofi (Euronext:…

atalurenGenzymeLicensingPharmaceuticalPTC TherapeuticsRare diseasesSanofi

Back to top